Heteroaryls and uses thereof

A method of treating a proliferative disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is hydrogen, C1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
• each of which being optionally substituted with 1-5 R6;
• R3 is C1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, 3-10-membered heterocyclyl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
• each of which being optionally substituted with 1-5 R6;
• wherein:
• each R6 independently is —CN, halo or -L3-R7 wherein:
• L3 is a bond, C1-4 alkylene, —O—, —N(Rx)—, —S—, —S(O)—, —S(O)2—, —C(O)—, —CO2—, N(Rx)C(O)—, —N(Rx)CO2—, —S(O)2NRx—, —N(Rx)S(O)2—, —OC(O)N(Rx)—, —N(Rx)C(O)N(Rx), —N(Rx)S(O)2N(Rx)— or —OC(O)—;
• each Rx, independently, is hydrogen or C1-4 alkyl;
• R7 is hydrogen, C1-6 aliphatic, 3-10-membered cycloaliphatic, phenyl, naphthyl, or 5-10-membered heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• X is a bond or C1-4 aliphatic;
• L1 is —N(R8)C(O)—, —C(O)—N(R9)—, —N(R10)S(O)2—, —S(O)2NR11—, —C(O)—, —C(S)—, —S(O)2—, —O—C(O)—, —C(O)—O—, —O—S(O)2—, —S(O)2—O—, —N(R13)C(O)N(R14)—, or —N(R15)S(O)2N(R16)—;
• and wherein
• each of R8, R9, R10, R11, R13, R14, R15, and R16, independently, is hydrogen or C1-4 alkyl;
• or X or L1 optionally joining with R1 to form an optionally substituted 5-6-membered heterocyclyl;
• R2 is hydrogen or C1-4 alkyl;
• L2 is a bond, —C(O)—, —S(O)2—, —C(O)—O—, —C(O)N(Ry)—, or —S(O)2N(Ry)—;
• wherein each Ry, independently, is hydrogen or C1-4 alkyl;
• each occurrence of R4 and R5, independently, is —CN, halo or -L4-R17 wherein
• L4 is C1-4 alkylene, —O—, —N(Rz)—, —S—, —S(O)—, —S(O)2—, —C(O)—, —CO2—, —C(O)N(Rz)—, —N(Rz)C(O)—,
• —N(Rz)C(O)O—, —S(O)2N(Rz)—, —N(Rz)S(O)2—, —OC(O)N(Rz)—, —N(Rz)C(O)N(Rz)—, —N(Rz)S(O)2N(Rz)— or —OC(O)—;
• each Rz, independently, is hydrogen or C1-4 alkyl, and
• R17 is hydrogen or C1-6 aliphatic;
• and
• each of m and n, independently, is 0-3;
• provided that
• if one R4 is located at the ring carbon between the ring nitrogen and the ring carbon to which —X-L1-R1 is located, X or L1 optionally joining with said R4 to form an optionally substituted 5-7-membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl;
• or
• if one R4 is located at either ring carbon adjacent to the ring nitrogen, said R4 optionally joining with the ring nitrogen to form an optionally substituted 5-7-membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl;
• or
• if L2 is a bond and R3 is phenyl, naphthyl, or heteroaryl, R2 optionally joining with a substituent of R3 to form an optionally substituted 5-7-membered heterocyclyl or an optionally substituted 5-6-membered heteroaryl.